Trial · NCT00922272
Results by group123
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 123
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF) | SPD489 (Open-label Phase) | -12.9 | Standard Deviation 10.04 | Units on a scale | |
| Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase | SPD489 (Open-label Phase) | 52.9 | Percent of participants | ||
| Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF) | SPD489 (Double-blind Phase) | 4.5 | Standard Error 2.14 | Units on a scale | |
| Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF) | Placebo (Double-blind Phase) | 2.2 | Standard Error 1.85 | Units on a scale | |
| Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | 71.4 | Percent of participants | ||
| Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase | Placebo (Double-blind Phase) | 82.4 | Percent of participants | ||
| Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase | SPD489 (Open-label Phase) | Affective Flattening | -0.9 | Standard Deviation 0.80 | Units on a scale |
| Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase | SPD489 (Open-label Phase) | Alogia | -0.9 | Standard Deviation 0.65 | Units on a scale |
| Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase | SPD489 (Open-label Phase) | Avolition-Apathy | -0.5 | Standard Deviation 0.81 | Units on a scale |
| Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase | SPD489 (Open-label Phase) | Anhedonia-Asociality | -0.7 | Standard Deviation 0.77 | Units on a scale |
| Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase | SPD489 (Open-label Phase) | Attention | -0.7 | Standard Deviation 0.80 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | Affective Flattening | 0.2 | Standard Error 0.17 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | Placebo (Double-blind Phase) | Affective Flattening | 0.2 | Standard Error 0.15 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | Alogia | 0.5 | Standard Error 0.21 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | Placebo (Double-blind Phase) | Alogia | 0.0 | Standard Error 0.19 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | Avolition-Apathy | 0.2 | Standard Error 0.16 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | Placebo (Double-blind Phase) | Avolition-Apathy | 0.1 | Standard Error 0.15 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | Anhedonia-Asociality | 0.3 | Standard Error 0.18 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | Placebo (Double-blind Phase) | Anhedonia-Asociality | 0.1 | Standard Error 0.16 | Units on a scale |
| Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase | SPD489 (Double-blind Phase) | Attention | 0.4 | Standard Error 0.18 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00922272/results